GlassScriptPhysician profile
Harry M Barnes
NPI 1356395214
$2,453.93
in general payments reported to CMS, 2019-2025
31 companies · $577 in 2025
The $577 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $32.68 · 2021: $279 · 2022: $336 · 2023: $510 · 2024: $583 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,649 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,648.72 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $347.86 | 2021-2025 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $311.65 | 2021-2025 | |
| Astellas Pharma US INC | $181.45 | 2019-2025 | Padcev, Vyloy, Xospata |
| Abbvie INC. | $163.36 | 2022-2025 | Venclexta |
| Pfizer INC. | $162.86 | 2019-2024 | |
| Janssen Biotech, INC. | $140.54 | 2021-2025 | Erleada, Darzalex, Tecvayli |
| Beigene USA, INC. | $133.07 | 2021-2025 | Brukinsa |
| Genzyme Corporation | $128.45 | 2019-2024 | |
| Deciphera Pharmaceuticals INC. | $114.60 | 2022-2025 | Qinlock, Romvimza, Tgct |
| Eisai INC. | $112.28 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $85.94 | 2019-2025 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $85.16 | 2022-2023 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $61.11 | 2023-2025 | Libtayo, Lynozyfic |
| Servier Pharmaceuticals LLC | $44.85 | 2022-2025 | |
| Beone Medicines USA, INC. | $42.49 | 2025 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $35.06 | 2025 | Ogsiveo |
| Glaxosmithkline, LLC. | $33.76 | 2023-2024 | Jemperli, Zejula |
| Seagen INC. | $30.41 | 2023 | Tukysa, Padcev |
| Helsinn Therapeutics (U.S.), INC. | $29.92 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $28.97 | 2019-2022 | |
| Kite Pharma, INC. | $26.58 | 2021-2023 | |
| Gilead Sciences, INC. | $24.74 | 2021-2022 | |
| Stemline Therapeutics INC. | $18.56 | 2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $18.25 | 2021 | |
| Kyowa Kirin, INC. | $17.62 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.49 | 2025 | |
| Amgen INC. | $14.31 | 2022 | |
| Incyte Corporation | $14.25 | 2021 | |
| Exelixis INC. | $14.24 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Clovis Oncology, INC. | $3.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.